Hikma Pharmaceuticals PLC (LON:HIK) Receives Average Rating of Moderate Buy from Brokerages

Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price target […]

Related Keywords

United States ,Canada ,America , ,Hikma Pharmaceuticals ,Royal Bank ,Hikma Pharmaceuticals Stock Performance ,Jpmorgan Chase Co ,News Ratings For Hikma Pharmaceuticals Daily ,Citigroup ,Hikma Pharmaceuticals Company Profile ,Analyst Recommendations For Hikma Pharmaceuticals ,Get Free Report ,Marketbeat Ratings ,Get Free ,North America ,Middle East ,North Africa ,Hikma Pharmaceuticals Daily ,Lon Hik ,Zhik ,Medical ,Ratings ,Consensus ,